DATABASE
Home
Database
Who We Are
What We Offer
Register
Sign In
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Name
Category
Agennix AG Schedules Conference Call on November 30, 2012 to Discuss Third Quarter 2012 Financial Results
News
Agennix Lung Cancer Drug in Doubt After Clinical Trial Failure
News
Agennix Plunges as Cancer Drug Fails in Trial: Frankfurt Mover
News
Agennix Reports Results of FORTIS-M Phase III Trial With Talactoferrin Alfa in Non-Small Cell Lung Cancer
News
Agenus Announces Initiation of Enrollment in NCI-Sponsored Randomized Trial of Prophage G-200 Vaccine With Avastin in Treatment of Brain Tumors
News
Agenus begins enrollment in NCI-Sponsored randomized trial of Prophage G-200
News
Agenus Eliminates its $39 Million Senior Notes and Completes $10 Million of New Debt Financing
News
Agenus Eliminates Its $39 Million Senior Notes and Completes $10 Million of New Debt Financing
News
AGENUS INC Files SEC form 10-Q, Quarterly Report
News
AGENUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
News
AGENUS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
News
AGENUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
News
AGENUS INC Financials
News
Agenus Inc.
Fund
Agenus Reports First Quarter 2013 Financial Results
News
Agenus to Report First Quarter 2013 Financial Results on April 24, 2013; Conference Call to Follow
News
Agenus' CEO Discusses Q1 2013 Results - Earnings Call Transcript
News
Agenus: Near-Term Drivers With A Market Opportunity Over $17 Billion
News
AGF Actions SICAV ACT. /3 DECIMALES
Fund
AGF American Growth Class Fund Front End Load Units (CAD)
Fund
AGF American Growth Class Fund Front End Load Units (CAD)
Fund
Agf Asset Management
Bank
Agf Asset Management
Bank
AGF Canadian Balanced Fund Trust Units - CAD Front End Load
Fund
AGF Canadian Balanced Fund Trust Units /CAD Deferred Sales Charge
Fund
Page 215 of 1100